Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurotherapeutics
Erschienen in: Neurotherapeutics 3/2016

01.07.2016 | Review

Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis

verfasst von: Hamid Salimi, Matthew D. Cain, Robyn S. Klein

Erschienen in: Neurotherapeutics | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Arboviruses are arthropod-borne viruses that exhibit worldwide distribution, contributing to systemic and neurologic infections in a variety of geographical locations. Arboviruses are transmitted to vertebral hosts during blood feedings by mosquitoes, ticks, biting flies, mites, and nits. While the majority of arboviral infections do not lead to neuroinvasive forms of disease, they are among the most severe infectious risks to the health of the human central nervous system. The neurologic diseases caused by arboviruses include meningitis, encephalitis, myelitis, encephalomyelitis, neuritis, and myositis in which virus- and immune-mediated injury may lead to severe, persisting neurologic deficits or death. Here we will review the major families of emerging arboviruses that cause neurologic infections, their neuropathogenesis and host neuroimmunologic responses, and current strategies for treatment and prevention of neurologic infections they cause.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Weaver SC, Winegar R, Manger ID, Forrester NL. Alphaviruses: Population genetics and determinants of emergence. Antiviral Res 2012;94:242–257.
2.
Powers AM, Brault AC, Shirako Y, et al. Evolutionary relationships and systematics of the alphaviruses. J Virol 2001;75:10118–10131.
3.
Rust RS, Thompson WH, Matthews CG, Beaty BJ, Chun RW. La Crosse and other forms of California encephalitis. J Child Neurol 1999;14:1–14.
4.
Go YY, Balasuriya UBR, Lee C-K. Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 2014;3:58–77.
5.
Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA. Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med 1997;336:1867–1874.
6.
Froeschle JE, Reeves WC. Serologic epidemiology of western equine and st. louis encephalitis virus infection in california. ii. analysis of inapparent infections in residents of an endemic area. Am J Epidemiol 1965;81:44–51.
7.
Atkins GJ, Atkins GJ. The pathogenesis of alphaviruses, the pathogenesis of alphaviruses. Int Sch Res Not Int Sch Res Not 2012;2013:e861912.
8.
Weaver SC, Ferro C, Barrera R, Boshell J, Navarro J-C. Venezuelan equine encephalitis. Annu Rev Entomol 2004;49:141–174.
9.
Centers for Disease Control and Prevention (CDC). Eastern equine encephalitis-New Hampshire and Massachusetts, August–September 2005. MMWR 2006;55:697–700.
10.
Adams AP, Navarro-Lopez R, Ramirez-Aguilar FJ, et al. Venezuelan equine encephalitis virus activity in the Gulf Coast region of Mexico, 2003–2010. PLoS Negl Trop Dis 2012;6:e1875.
11.
Lemant J, Boisson V, Winer A, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit Care Med 2008;36:2536–2541.
12.
Gérardin P, Barau G, Michault A, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. PLoS Med 2008;5:e60.
13.
Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. AJNR Am J Neuroradiol 2008;29:1636–1637.
14.
Lebrun G, Chadda K, Reboux A-H, Martinet O, Gaüzère B-A. Guillain-Barré syndrome after chikungunya infection. Emerg Infect Dis 2009;15:495–496.
15.
Gérardin P, Couderc T, Bintner M, et al. Chikungunya virus-associated encephalitis: A cohort study on La Réunion Island, 2005–2009. Neurology 2016;86:94–102.
16.
Lindsey NP, Lehman JA, Staples JE, Fischer M. West Nile virus and other nationally notifiable arboviral diseases - United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:929–934.
17.
Selvey LA, Dailey L, Lindsay M, et al. The changing epidemiology of Murray Valley encephalitis in Australia: the 2011 outbreak and a review of the literature. PLoS Negl Trop Dis 2014;8:e2656.
18.
Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89:766–774, 774A–774E.
19.
Centers for Disease Control and Prevention (CDC). Intrauterine West Nile virus infection-New York, 2002. MMWR 2002;51:1135–1136.
20.
Alpert SG, Fergerson J, Noël LP. Intrauterine West Nile virus: ocular and systemic findings. Am J Ophthalmol 2003;136:733–735.
21.
Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet Lond Engl 2000;355:1053–1059.
22.
Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15:1347–1350.
23.
Lazear HM, Govero J, Smith AM, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe 2016;19:720-730.
24.
Carteaux G, Maquart M, Bedet A, et al. Zika Virus Associated with Meningoencephalitis. N Engl J Med 2016;374:1595–1596.
25.
Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. Euro Surveill 2014;19:20720.
26.
Wong P-SJ, Li MI, Chong C-S, Ng L-C, Tan C-H. Aedes (Stegomyia) albopictus (Skuse): a potential vector of Zika virus in Singapore. PLoS Negl Trop Dis 2013;7:e2348.
27.
Brasil P, Pereira JP, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. N Engl J Med 2016 Mar 4 [Epub ahead of print].
28.
Carod-Artal FJ. Epidemiology and neurological complications of infection by the Zika virus: a new emerging neurotropic virus. Rev Neurol 2016;62:317–328.
29.
30.
Foy BD, Kobylinski KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011;17:880–882.
31.
McCarthy M. Zika virus was transmitted by sexual contact in Texas, health officials report. BMJ 2016;352:i720.
32.
Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau V-M. Potential sexual transmission of Zika virus. Emerg Infect Dis 2015;21:359–361.
33.
Atkinson B, Hearn P, Afrough B, et al. Detection of Zika virus in semen. Emerg Infect Dis 2016;22:940.
34.
Soldan SS, González-Scarano F. Emerging infectious diseases: the Bunyaviridae. J Neurovirol 2005;11:412–423.
35.
Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus introduction and establishment in the United States and European Union. Emerg Microbes Infect 2013;2:e81.
36.
El-Akkad AM. Rift Valley fever outbreak in Egypt. October–December 1977. J Egypt Public Health Assoc 1978;53:123–128.
37.
Ikegami T, Makino S. The pathogenesis of Rift Valley fever. Viruses 2011;3:493–519.
38.
Cusi MG, Savellini GG, Zanelli G. Toscana virus epidemiology: from Italy to beyond. Open Virol J 2010;4:22–28.
39.
Dincer E, Gargari S, Ozkul A, Ergunay K. Potential animal reservoirs of Toscana virus and coinfections with Leishmania infantum in Turkey. Am J Trop Med Hyg 2015;92:690–697.
40.
Bowen GS, McLean RG, Shriner RB, et al. The ecology of Colorado tick fever in Rocky Mountain National Park in 1974. II. Infection in small mammals. Am J Trop Med Hyg 1981;30:490–496.
41.
McLean RG, Carey AB, Kirk LJ, Francy DB. Ecology of porcupines (Erethizon dorsatum) and Colorado tick fever virus in Rocky Mountain National Park, 1975–1977. J Med Entomol 1993;30:236–238.
42.
Klasco R. Colorado tick fever. Med Clin North Am 2002;86:435–440, ix.
43.
Yendell SJ, Fischer M, Staples JE. Colorado tick fever in the United States, 2002–2012. Vector Borne Zoonotic Dis 2015;15:311–316.
44.
Pedrosa PBS, Cardoso TAO. Viral infections in workers in hospital and research laboratory settings: a comparative review of infection modes and respective biosafety aspects. Int J Infect Dis 2011;15:e366-e376.
45.
Taylor KG, Paessler S. Pathogenesis of Venezuelan equine encephalitis. Vet Microbiol 2013;167:145–150.
46.
Centers for Disease Control and Prevention (CDC). Venezuelan equine encephalitis—Colombia, 1995. MMWR Morb Mortal Wkly Rep 1995;44:721–724.
47.
Johnson KM, Shelokov A, Peralta PH, Dammin GJ, Young NA. Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man. Am J Trop Med Hyg 1968;17:432–440.
48.
Hatanpaa KJ, Kim JH. Neuropathology of viral infections. Handb Clin Neurol 2014;123:193–214.
49.
Miller LD, Pearson JE, Muhm RL. A comparison of clinical manifestations and pathology of the equine encephalidites: VEE, WEE, EEE. Proc Annu Meet U S Anim Health Assoc 1973;(77):629–31.
50.
Steele KE, Twenhafel NA. REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol 2010;47:790–805.
51.
Hanson RP, Sulkin SE, Beuscher EL, Hammon WM, McKinney RW, Work TH. Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. Science 1967;158:1283–1286.
52.
Sourisseau M, Schilte C, Casartelli N, et al. Characterization of reemerging chikungunya virus. PLoS Pathog 2007;3:e89.
53.
Schilte C, Staikowsky F, Staikovsky F, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 2013;7:e2137.
54.
Lenglet Y, Barau G, Robillard P-Y, et al. [Chikungunya infection in pregnancy: Evidence for intrauterine infection in pregnant women and vertical transmission in the parturient. Survey of the Reunion Island outbreak]. J Gynécologie Obstétrique Biol Reprod 2006;35:578–583.
55.
Solomon T. Flavivirus encephalitis. N Engl J Med 2004;351:370–378.
56.
Vaughn DW, Hoke CH. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992;14:197–221.
57.
Porterfield JS. Exotic viral infections. Chapman & Hall Medical; 1995, pp. 175-181.
58.
Rust RS. Human arboviral encephalitis. Semin Pediatr Neurol 2012;19:130–151.
59.
Dutta K, Basu A. Japanese encephalitis: A tale of inflammation and degeneration in the central nervous system. In: Peterson PK, Toborek M, editors. Neuroinflammation and Neurodegeneration. Springer New York; 2014. pp. 309–335.
60.
Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196–2203.
61.
Macedo de Oliveira A, Beecham BD, Montgomery SP, et al. West Nile virus blood transfusion-related infection despite nucleic acid testing. Transfusion 2004;44:1695–1699.
62.
Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005;11:1174–1179.
63.
Centers for Disease Control and Prevention (CDC). Acute flaccid paralysis syndrome associated with West Nile virus infection—Mississippi and Louisiana, July–August 2002. MMWR Morb Mortal Wkly Rep 2002;51:825–828.
64.
Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003;290:511–515.
65.
Wang H, Siddharthan V, Kesler KK, et al. Fatal neurological respiratory insufficiency is common among viral encephalitides. J Infect Dis 2013;208:573–583.
66.
Oyer RJ, David Beckham J, Tyler KL. West Nile and St. Louis encephalitis viruses. Handb Clin Neurol 2014;123:433–447.
67.
Fratkin JD, Leis AA, Stokic DS, Slavinski SA, Geiss RW. Spinal cord neuropathology in human West Nile virus infection. Arch Pathol Lab Med 2004;128:533–537.
68.
Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurol India 2010;58:585–591.
69.
Verma R, Sharma P, Garg RK, Atam V, Singh MK, Mehrotra HS. Neurological complications of dengue fever: Experience from a tertiary center of north India. Ann Indian Acad Neurol 2011;14:272–278.
70.
Madi D, Achappa B, Ramapuram JT, Chowta N, Laxman M, Mahalingam S. Dengue encephalitis-A rare manifestation of dengue fever. Asian Pac J Trop Biomed 2014;4(Suppl, 1):S70-S72.
71.
Christo PP. Encephalitis by dengue virus and other arboviruses. Arq Neuropsiquiatr 2015;73:641–643.
72.
Dick GWA, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952;46:509–520.
73.
Duffy MR, Chen T-H, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009;360:2536–2543.
74.
Sarno M, Sacramento GA, Khouri R, et al. Zika virus infection and stillbirths: A case of hydrops fetalis, hydranencephaly and fetal demise. PLoS Negl Trop Dis 2016;10:e0004517.
75.
Ventura CV, Maia M, Ventura BV, et al. Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. Arq Bras Oftalmol 2016;79:1–3.
76.
Ventura CV, Maia M, Bravo-Filho V, Góis AL, Belfort R. Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet 2016;387:228.
77.
Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet Gynecol 2016;47:6–7.
78.
Schuler-Faccini L, Ribeiro EM, Feitosa IML, et al. Possible association between Zika virus infection and microcephaly – Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016;65:59–62.
79.
Wiley CA, Bhardwaj N, Ross TM, Bissel SJ. Emerging infections of CNS: Avian influenza A virus, Rift Valley fever virus and human parechovirus. Brain Pathol 2015;25:634–650.
80.
Bartels S, de Boni L, Kretzschmar HA, Heckmann JG. Lethal encephalitis caused by the Toscana virus in an elderly patient. J Neurol 2012;259:175–177.
81.
Leiby DA, Gill JE. Transfusion-transmitted tick-borne infections: a cornucopia of threats. Transfus Med Rev 2004;18:293–306.
82.
Goodpasture HC, Poland JD, Francy DB, Bowen GS, Horn KA. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973–1974. Ann Intern Med 1978;88:303–310.
83.
Berg PJ, Smallfield S, Svien L. An investigation of depression and fatigue post West Nile virus infection. S D Med 2010;63:127–129, 131–133.
84.
Hoffman JE, Paschal KA. Functional outcomes of adult patients with West Nile virus admitted to a rehabilitation hospital. J Geriatr Phys Ther 2013;36:55–62.
85.
Berner YN, Lang R, Chowers MY. Outcome of West Nile fever in older adults. J Am Geriatr Soc 2002;50:1844–1846.
86.
Arciniegas DB, Anderson CA. Viral encephalitis: neuropsychiatric and neurobehavioral aspects. Curr Psychiatry Rep 2004;6:372–379.
87.
Klee AL, Maidin B, Edwin B, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 2004;10:1405–1411.
88.
Carson PJ, Konewko P, Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis 2006;43:723–730.
89.
Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis 2006;12:1260–1262.
90.
Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol 2006;60:286–300.
91.
Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 2007;44:1617–1624.
92.
Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol 2010;32:81–87.
93.
Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol 2008;2:477–499.
94.
Cvejic E, Lemon J, Hickie IB, Lloyd AR, Vollmer-Conna U. Neurocognitive disturbances associated with acute infectious mononucleosis, Ross River fever and Q fever: A preliminary investigation of inflammatory and genetic correlates. Brain Behav Immun 2014;36:207–214.
95.
Fitch WM, Artsob H. Powassan encephalitis in new brunswick. Can Fam Physician 1990;36:1289–1290.
96.
Lessell S, Collins TE. Ophthalmoplegia in Powassan encephalitis. Neurology 2003;60:1726–1727.
97.
Greve KW, Houston RJ, Adams D, et al. The neurobehavioural consequences of St. Louis encephalitis infection. Brain Inj 2002;16:917–927.
98.
Monnet FP. Behavioural disturbances following Japanese B encephalitis. Eur Psychiatry 2003;18:269–273.
99.
Labeaud AD, Bashir F, King CH. Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections. Popul Health Metr 2011;9:1.
100.
Joshi R, Mishra PK, Joshi D, et al. Clinical presentation, etiology, and survival in adult acute encephalitis syndrome in rural Central India. Clin Neurol Neurosurg 2013;115:1753–1761.
101.
Styer LM, Kent KA, Albright RG, Bennett CJ, Kramer LD, Bernard KA. Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog 2007;3:1262–1270.
102.
Garcia-Tapia D, Hassett DE, Mitchell WJ, Johnson GC, Kleiboeker SB. West Nile virus encephalitis: sequential histopathological and immunological events in a murine model of infection. J Neurovirol 2007;13:130–138.
103.
Johnston LJ, Halliday GM, King NJ. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J Invest Dermatol 2000;114:560–568.
104.
Lim P-Y, Behr MJ, Chadwick CM, Shi P-Y, Bernard KA. Keratinocytes are cell targets of West Nile virus in vivo. J Virol 2011;85:5197–5201.
105.
MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000;74:914–922.
106.
Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, Ryman KD. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. J Virol 2008;82:10634–10646.
107.
Vogel P, Kell WM, Fritz DL, Parker MD, Schoepp RJ. Early events in the pathogenesis of eastern equine encephalitis virus in mice. Am J Pathol 2005;166:159–171.
108.
Bai F, Kong K-F, Dai J, et al. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J Infect Dis 2010;202:1804–1812.
109.
Ben-Nathan D, Huitinga I, Lustig S, van Rooijen N, Kobiler D. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch Virol 1996;141:459–469.
110.
Samuel MA, Whitby K, Keller BC, et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol 2006;80:7009–7019.
111.
Goto A, Hayasaka D, Yoshii K, Mizutani T, Kariwa H, Takashima I. A BHK-21 cell culture-adapted tick-borne encephalitis virus mutant is attenuated for neuroinvasiveness. Vaccine 2003;21:4043–4051.
112.
Errett JS, Suthar MS, McMillan A, Diamond MS, Gale M. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol 2013;87:11416–11425.
113.
Akhrymuk I, Frolov I, Frolova EI. Both RIG-I and MDA5 detect alphavirus replication in concentration-dependent mode. Virology 2016;487:230–241.
114.
Suthar MS, Ma DY, Thomas S, et al. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 2010;6:e1000757.
115.
Lazear HM, Pinto AK, Ramos HJ, et al. Pattern recognition receptor MDA5 modulates CD8+ T cell-dependent clearance of West Nile virus from the central nervous system. J Virol 2013;87:11401–11415.
116.
Daffis S, Samuel MA, Suthar MS, Gale M, Diamond MS. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 2008;82:10349–10358.
117.
Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004;10:1366–1373.
118.
Town T, Bai F, Wang T, et al. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009;30:242–253.
119.
Taylor KG, Woods TA, Winkler CW, Carmody AB, Peterson KE. Age-dependent myeloid dendritic cell responses mediate resistance to La Crosse virus-induced neurological disease. J Virol 2014;88:11070–11079.
120.
Pinto AK, Ramos HJ, Wu X, et al. Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog 2014;10:e1004086.
121.
Samuel MA, Diamond MS. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 2005;79:13350–13361.
122.
Grieder FB, Vogel SN. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 1999;257:106–118.
123.
Schoneboom BA, Lee JS, Grieder FB. Early expression of IFN-alpha/beta and iNOS in the brains of Venezuelan equine encephalitis virus-infected mice. J Interferon Cytokine Res 2000;2:205–215.
124.
White LJ, Wang J-G, Davis NL, Johnston RE. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: Effect of an attenuating mutation in the 5′ untranslated region. J Virol 2001;75:3706–3718.
125.
Müller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918–1921.
126.
Schuh T, Schultz J, Moelling K, Pavlovic J. DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4+ T cells. Hum Gene Ther 1999;10:1649–1658.
127.
Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004;15:101–109.
128.
Lukaszewski RA, Brooks TJ. Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 2000;74:5006–5015.
129.
Gilfoy FD, Mason PW. West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J Virol 2007;81:11148–11158.
130.
Atasheva S, Akhrymuk M, Frolova EI, Frolov I. New PARP gene with an anti-alphavirus function. J Virol 2012;86:8147–8160.
131.
Atasheva S, Frolova EI, Frolov I. Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication. J Virol 2014;88:2116–2130.
132.
Mudhasani R, Tran JP, Retterer C, et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 2013;87:8451–8464.
133.
Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003;77:12941–12949.
134.
Halevy M, Akov Y, Ben-Nathan D, Kobiler D, Lachmi B, Lustig S. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. Arch Virol 1994;137:355–370.
135.
Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003;198:1853–1862.
136.
Charles PC, Trgovcich J, Davis NL, Johnston RE. Immunopathogenesis and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology 2001;284:190–202.
137.
Shrestha B, Wang T, Samuel MA, et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 2006;80:5338–5348.
138.
Wang T, Scully E, Yin Z, et al. IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J Immunol 1950 2003;171:2524–2531.
139.
Samuel MA, Wang H, Siddharthan V, Morrey JD, Diamond MS. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A 2007;104:17140–17145.
140.
Wang H, Siddharthan V, Hall JO, Morrey JD. West Nile virus preferentially transports along motor neuron axons after sciatic nerve injection of hamsters. J Neurovirol 2009;15:293–299.
141.
Hunsperger EA, Roehrig JT. Nocodazole delays viral entry into the brain following footpad inoculation with West Nile virus in mice. J Neurovirol 2009;15:211–218.
142.
Monath TP, Cropp CB, Harrison AK. Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Investig J Tech Methods Pathol 1983;48:399–410.
143.
McMinn PC, Dalgarno L, Weir RC. A comparison of the spread of Murray Valley encephalitis viruses of high or low neuroinvasiveness in the tissues of Swiss mice after peripheral inoculation. Virology 1996;220:414–r23.
144.
Charles PC, Walters E, Margolis F, Johnston RE. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 1995;208:662–671.
145.
Honnold SP, Mossel EC, Bakken RR, et al. Eastern equine encephalitis virus in mice II: pathogenesis is dependent on route of exposure. Virol J 2015;12:154.
146.
Bennett RS, Cress CM, Ward JM, Firestone C-Y, Murphy BR, Whitehead SS. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol J 2008;5:25.
147.
Danes L, Kufner J, Hrusková J, Rychterová V. The role of the olfactory route on infection of the respiratory tract with Venezuelan equine encephalitis virus in normal and operated Macaca rhesus monkeys. I. Results of virological examination; II. Results of histological examination. Acta Virol 1973;17:50–56.
148.
Reed DS, Lackemeyer MG, Garza NL, et al. Severe encephalitis in cynomolgus macaques exposed to aerosolized Eastern equine encephalitis virus. J Infect Dis 2007;196:441–450.
149.
Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 2010;64:328–363.
150.
Verma S, Lo Y, Chapagain M, et al. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier. Virology 2009;385:425–433.
151.
Li F, Wang Y, Yu L, et al. Viral infection of the central nervous system and neuroinflammation precede blood-brain barrier disruption during Japanese encephalitis virus infection. J Virol 2015;89:5602–5614.
152.
Daniels BP, Holman DW, Cruz-Orengo L, Jujjavarapu H, Durrant DM, Klein RS. Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals. mBio 2014;5:e01476-14.
153.
Suen WW, Prow NA, Hall RA, Bielefeldt-Ohmann H. Mechanism of West Nile virus neuroinvasion: A critical appraisal. Viruses 2014;6:2796–2825.
154.
Myint KSA, Kipar A, Jarman RG, et al. Neuropathogenesis of Japanese encephalitis in a primate model. PLoS Negl Trop Dis 2014;8:e2980.
155.
Hasebe R, Suzuki T, Makino Y, et al. Transcellular transport of West Nile virus-like particles across human endothelial cells depends on residues 156 and 159 of envelope protein. BMC Microbiol 2010;10:165.
156.
Liou ML, Hsu CY. Japanese encephalitis virus is transported across the cerebral blood vessels by endocytosis in mouse brain. Cell Tissue Res 1998;293:389–394.
157.
Lazear HM, Daniels BP, Pinto AK, et al. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med 2015;7:284ra59.
158.
Roe K, Kumar M, Lum S, Orillo B, Nerurkar VR, Verma S. West Nile virus-induced disruption of the blood–brain barrier in mice is characterized by the degradation of the junctional complex proteins and increase in multiple matrix metalloproteinases. J Gen Virol 2012;93:1193–1203.
159.
Morrey JD, Olsen AL, Siddharthan V, et al. Increased blood–brain barrier permeability is not a primary determinant for lethality of West Nile virus infection in rodents. J Gen Virol 2008;89:467–473.
160.
Růžek D, Salát J, Singh SK, Kopecký J. Breakdown of the blood-brain barrier during tick-borne encephalitis in mice is not dependent on CD8+ T-cells. PloS One 2011;6:e20472.
161.
Schäfer A, Brooke CB, Whitmore AC, Johnston RE. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J Virol 2011;85:10682–10690.
162.
Schäfer A, Whitmore AC, Konopka JL, Johnston RE. Replicon particles of Venezuelan equine encephalitis virus as a reductionist murine model for encephalitis. J Virol 2009;83:4275–4286.
163.
Sharma A, Bhomia M, Honnold SP, Maheshwari RK. Role of adhesion molecules and inflammation in Venezuelan equine encephalitis virus infected mouse brain. Virol J 2011;8:197.
164.
Roe K, Orillo B, Verma S. West Nile virus-induced cell adhesion molecules on human brain microvascular endothelial cells regulate leukocyte adhesion and modulate permeability of the in vitro blood-brain barrier model. PLoS ONE 2014;9:e102598.
165.
King NJ, Shrestha B, Kesson AM. Immune modulation by flaviviruses. Adv Virus Res 2003;60:121–155.
166.
Dai J, Wang P, Bai F, Town T, Fikrig E. ICAM-1 participates in the entry of West Nile virus into the central nervous system. J Virol 2008;82:4164–4168.
167.
Myint KS, Raengsakulrach B, Young GD, et al. Production of lethal infection that resembles fatal human disease by intranasal inoculation of macaques with Japanese encephalitis virus. Am J Trop Med Hyg 1999;60:338–342.
168.
Hase T, Dubois DR, Summers PL. Comparative study of mouse brains infected with Japanese encephalitis virus by intracerebral or intraperitoneal inoculation. Int J Exp Pathol 1990;71:857–869.
169.
Matthews V, Robertson T, Kendrick T, Abdo M, Papadimitriou J, Mcminn P. Morphological features of Murray Valley encephalitis virus infection in the central nervous system of swiss mice. Int J Exp Pathol 2000;81:31–40.
170.
Klein RS, Lin E, Zhang B, et al. Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol 2005;79:11457–11466.
171.
Murphy FA, Coleman PH, Harrison AK, Gary GW. Colorado tick fever virus: an electron microscopic study. Virology 1968;35:28–40.
172.
Isachkova LM, Shestopalova NM, Frolova MP, Reingold VN. Light and electron microscope study of the neurotropism of Powassan virus strain P-40. Acta Virol 1979;23:40–44.
173.
Guo J. Studies using IPS cells support a possible link between ZIKA and microcephaly. Cell Biosci 2016;6:28.
174.
Sirohi D, Chen Z, Sun L, et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 2016;352:467–470.
175.
Tang H, Hammack C, Ogden SC, et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell 2016;18:587-590.
176.
Nowakowski TJ, Pollen AA, Di Lullo E, Sandoval-Espinosa C, Bershteyn M, Kriegstein AR. Expression analysis highlights AXL as a candidate Zika virus entry receptor in neural stem cells. Cell Stem Cell 2016;18:591-596.
177.
Lee E, Lobigs M. Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry. J Virol 2000;74:8867–8875.
178.
Davis NL, Grieder FB, Smith JF, et al. A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis. Arch Virol Suppl 1994;9:99–109.
179.
Lee E, Hall RA, Lobigs M. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 2004;78:8271–8280.
180.
Aguilar PV, Adams AP, Wang E, et al. Structural and nonstructural protein genome regions of eastern equine encephalitis virus are determinants of interferon sensitivity and murine virulence. J Virol 2008;82:4920–4930.
181.
Chen C-J, Ou Y-C, Lin S-Y, et al. Glial activation involvement in neuronal death by Japanese encephalitis virus infection. J Gen Virol 2010;91:1028–1037.
182.
Cho H, Diamond MS. Immune responses to West Nile virus infection in the central nervous system. Viruses 2012;4:3812–3830.
183.
Samuel MA, Morrey JD, Diamond MS. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol 2007;81:2614–2623.
184.
Růžek D, Vancová M, Tesařová M, Ahantarig A, Kopecký J, Grubhoffer L. Morphological changes in human neural cells following tick-borne encephalitis virus infection. J Gen Virol 2009;90:1649–1658.
185.
Jackson AC, Rossiter JP. Apoptotic cell death is an important cause of neuronal injury in experimental Venezuelan equine encephalitis virus infection of mice. Acta Neuropathol 1997;93:349–353.
186.
Schoneboom BA, Catlin KMK, Marty AM, Grieder FB. Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice. J Neuroimmunol 2000;109:132–146.
187.
Chambers TJ, Diamond MS. Pathogenesis of flavivirus encephalitis. Adv Virus Res 2003;60:273–342.
188.
Yang J-S, Ramanathan MP, Muthumani K, et al. Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis 2002;8:1379–1384.
189.
Yang T-C, Shiu S-L, Chuang P-H, et al. Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells. Virus Res 2009;143:77–85.
190.
Prikhod’ko GG, Prikhod’ko EA, Pletnev AG, Cohen JI. Langat flavivirus protease NS3 binds caspase-8 and induces apoptosis. J Virol 2002;76:5701–5710.
191.
Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J Virol 2008;82:609–616.
192.
Mukherjee P, Woods TA, Moore RA, Peterson KE. Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death. Immunity 2013;38:705–716.
193.
Szretter KJ, Samuel MA, Gilfillan S, Fuchs A, Colonna M, Diamond MS. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile virus pathogenesis. J Virol 2009;83:9329–9338.
194.
Sharma A, Bhattacharya B, Puri RK, Maheshwari RK. Venezuelan equine encephalitis virus infection causes modulation of inflammatory and immune response genes in mouse brain. BMC Genomics 2008;9:289.
195.
Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation 2010;7:73.
196.
Guadagno J, Swan P, Shaikh R, Cregan SP. Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells. Cell Death Dis 2015;6:e1779.
197.
Zou J, Wang Y-X, Dou F-F, et al. Glutamine synthetase downregulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem Int 2010;56:577–584.
198.
Palus M, Bílý T, Elsterová J, et al. Infection and injury of human astrocytes by tick-borne encephalitis virus. J Gen Virol 2014;95:2411–2426.
199.
Verma S, Kumar M, Nerurkar VR. Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes. J Gen Virol 2011;92:507–515.
200.
Bhowmick S, Duseja R, Das S, Appaiahgiri MB, Vrati S, Basu A. Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis. Neurosci Lett 2007;414:45–50.
201.
Diniz JAP, Da Rosa APAT, Guzman H, et al. West Nile virus infection of primary mouse neuronal and neuroglial cells: the role of astrocytes in chronic infection. Am J Trop Med Hyg 2006;75:691–696.
202.
Ghoshal A, Das S, Ghosh S, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007;55:483–496.
203.
Verma S, Kumar M, Gurjav U, Lum S, Nerurkar VR. Reversal of West Nile virus-induced blood–brain barrier disruption and tight junction proteins degradation by matrix metalloproteinases inhibitor. Virology 2010;397:130–138.
204.
Schoneboom BA, Fultz MJ, Miller TH, McKinney LC, Grieder FB. Astrocytes as targets for Venezuelan equine encephalitis virus infection. J Neurovirol 1999;5:342–354.
205.
Wang P, Dai J, Bai F, et al. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol 2008;82:8978–8985.
206.
Kreil TR, Eibl MM. Nitric oxide and viral infection: no antiviral activity against a flavivirusin vitro,and evidence for contribution to pathogenesis in experimental infection in vivo. Virology 1996;219:304–306.
207.
Andrews DM, Matthews VB, Sammels LM, Carrello AC, McMinn PC. The severity of murray valley encephalitis in mice is linked to neutrophil infiltration and inducible nitric oxide synthase activity in the central nervous system. J Virol 1999;73:8781–8790.
208.
Palus M, Vojtíšková J, Salát J, et al. Mice with different susceptibility to tick-borne encephalitis virus infection show selective neutralizing antibody response and inflammatory reaction in the central nervous system. J Neuroinflammation 2013;10:77.
209.
McKimmie CS, Fazakerley JK. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J Neuroimmunol 2005;169:116–125.
210.
Verbruggen P, Ruf M, Blakqori G, et al. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J Biol Chem 2011;286:3681–3692.
211.
Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101–105.
212.
Han YW, Choi JY, Uyangaa E, et al. Distinct dictation of Japanese encephalitis virus-induced neuroinflammation and lethality via triggering TLR3 and TLR4 signal pathways. PLoS Pathog 2014;10:e1004319.
213.
Kindberg E, Vene S, Mickiene A, Lundkvist Å, Lindquist L, Svensson L. A functional Toll-like receptor 3 gene (TLR3) may be a risk factor for tick-borne encephalitis virus (TBEV) infection. J Infect Dis 2011;203:523–528.
214.
Nazmi A, Mukherjee S, Kundu K, et al. TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection. Neurobiol Dis 2014;69:235–247.
215.
Baker DG, Woods TA, Butchi NB, et al. Toll-like receptor 7 suppresses virus replication in neurons but does not affect viral pathogenesis in a mouse model of Langat virus infection. J Gen Virol 2013;94:336–347.
216.
Sharma A, Maheshwari RK. Oligonucleotide array analysis of Toll-like receptors and associated signalling genes in Venezuelan equine encephalitis virus-infected mouse brain. J Gen Virol 2009;90:1836–1847.
217.
Delhaye S, Paul S, Blakqori G, et al. Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci U S A 2006;103:7835–7840.
218.
Kallfass C, Ackerman A, Lienenklaus S, Weiss S, Heimrich B, Staeheli P. Visualizing production of beta interferon by astrocytes and microglia in brain of La Crosse virus-infected mice. J Virol 2012;86:11223–11230.
219.
Binder GK, Griffin DE. Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science 2001;293:303–306.
220.
Binder GK, Griffin DE. Immune-mediated clearance of virus from the central nervous system. Microbes Infect Inst Pasteur 2003;5:439–448.
221.
Diamond MS, Shrestha B, Mehlhop E, Sitati E, Engle M. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 2003;16:259–278.
222.
Sitati EM, Diamond MS. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 2006;80:12060–12069.
223.
Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988;141:3606–3610.
224.
Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 2001;951:286–297.
225.
Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 1986;67:229–234.
226.
Ravi V, Parida S, Desai A, Chandramuki A, Gourie-Devi M, Grau GE. Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. J Med Virol 1997;51:132–136.
227.
Burke DS, Lorsomrudee W, Leake CJ, et al. Fatal Outcome in Japanese Encephalitis. Am J Trop Med Hyg 1985;34:1203–1210.
228.
Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991;254:856–860.
229.
Dodd KA, McElroy AK, Jones MEB, Nichol ST, Spiropoulou CF. Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses. J Virol 2013;87:6161–6171.
230.
Anderson GW, Lee JO, Anderson AO, Powell N, Mangiafico JA, Meadors G. Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats. Vaccine 1991;9:710–714.
231.
Yun NE, Peng B-H, Bertke AS, et al. CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus. Vaccine 2009;27:4064–4073.
232.
Brooke CB, Deming DJ, Whitmore AC, White LJ, Johnston RE. T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody. J Virol 2010;84:4556–4568.
233.
McCandless EE, Zhang B, Diamond MS, Klein RS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A 2008;105:11270–11275.
234.
Zhang B, Chan YK, Lu B, Diamond MS, Klein RS. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol 2008;180:2641–2649.
235.
Durrant DM, Daniels BP, Klein RS. IL-1R1 signaling regulates CXCL12-mediated T cell localization and fate within the central nervous system during West Nile virus encephalitis. J Immunol 2014;193:4095–4106.
236.
Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol 2004;78:8312–8321.
237.
Murali-Krishna K, Ravi V, Manjunath R. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J Gen Virol 1996;77:705–714.
238.
Desai A, Murali-Krishna K, Ramireddy B, Ravi V, Manjunath R. In vivo clearance of Japanese encephalitis virus by adoptively transferred virus specific cytotoxic T lymphocytes. J Biosci 1997;22:33–45.
239.
Wang Y, Lobigs M, Lee E, Müllbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 2003;77:13323–13334.
240.
Lanteri MC, O’Brien KM, Purtha WE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest 2009;119:3266–3277.
241.
Gelpi E, Preusser M, Laggner U, et al. Inflammatory response in human tick-borne encephalitis: analysis of postmortem brain tissue. J Neurovirol 2006;12:322–327.
242.
Růžek D, Salát J, Palus M, et al. CD8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology 2009;384:1–6.
243.
Brien JD, Uhrlaub JL, Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J Immunol 2008;181:8568–8575.
244.
Liu T, Chambers TJ. Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes. J Virol 2001;75:2107–2118.
245.
Steele KE, Davis KJ, Stephan K, Kell W, Vogel P, Hart MK. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet Pathol 1998;35:386–397.
246.
Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect 2006;134:1325–1332.
247.
Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261–264.
248.
Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Žugich J. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009;206:2735–2745.
249.
Kong K-F, Delroux K, Wang X, et al. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. J Virol 2008;82:7613–7623.
250.
Xie G, Luo H, Pang L, et al. Dysregulation of Toll-like receptor 7 compromises innate and adaptive T cell responses and host resistance to an attenuated West Nile virus infection in old mice. J Virol 2015;90:1333–1344.
251.
Das S, Basu A. Japanese encephalitis virus infects neural progenitor cells and decreases their proliferation. J Neurochem 2008;106:1624–1636.
252.
McJunkin JE, de los Reyes EC, Irazuzta JE, et al. La Crosse encephalitis in children. N Engl J Med 2001;344:801–807.
253.
Castorena KM, Peltier DC, Peng W, Miller DJ. Maturation-dependent responses of human neuronal cells to western equine encephalitis virus infection and type I interferons. Virology 2008;372:208–220.
254.
Schultz KLW, Vernon PS, Griffin DE. Differentiation of neurons restricts arbovirus replication and increases expression of the alpha isoform of IRF-7. J Virol 2015;89:48–60.
255.
Ryman KD, Gardner CL, Meier KC, Biron CA, Johnston RE, Klimstra WB. Early restriction of alphavirus replication and dissemination contributes to age-dependent attenuation of systemic hyperinflammatory disease. J Gen Virol 2007;88:518–529.
256.
Miner JJ, Cao B, Govero J, et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 2016 (in press).
257.
Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35–40.
258.
Kindberg E, Mickienė A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008;197:266–269.
259.
Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009;5:e1000321.
260.
Glass WG, Lim JK, Cholera R, Pletnev AG, Gao J-L, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005;202:1087–1098.
261.
Bigham AW, Buckingham KJ, Husain S, et al. Host genetic risk factors for West Nile virus infection and disease progression. PLoS ONE 2011;6:e24745.
262.
Barkhash AV, Perelygin AA, Babenko VN, et al. Variability in the 2’-5’-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. J Infect Dis 2010;202:1813–1818.
263.
Case KL, West RM, Smith MJ. Histocompatibility antigens and La Crosse encephalitis. J Infect Dis 1993;168:358–360.
264.
Dutta K, Basu A. Use of minocycline in viral infections. Indian J Med Res 2011;133:467–470.
265.
Mishra MK, Ghosh D, Duseja R, Basu A. Antioxidant potential of minocycline in Japanese Encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 2009;54:464–470.
266.
Das S, Dutta K, Kumawat KL, Ghoshal A, Adhya D, Basu A. Abrogated inflammatory response promotes neurogenesis in a murine model of Japanese encephalitis. PLoS One 2011;6:e17225.
267.
Kumar R, Basu A, Sinha S, et al. Role of oral minocycline in acute encephalitis syndrome in India - a randomized controlled trial. BMC Infect Dis 2016;16:67.
268.
Swarup V, Ghosh J, Mishra MK, Basu A. Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother 2008;61:679–688.
269.
Sehgal N, Kumawat KL, Basu A, Ravindranath V. Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection. PLoS One 2012;7:e35427.
270.
Dutta K, Ghosh D, Basu A. Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system. J Neuroimmune Pharmacol 2009;4:328–337.
271.
Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP). Inactivated Japanese encephalitis virus vaccine. MMWR 1993;42:1–15.
272.
Anon. A new Japanese encephalitis vaccine (Ixiaro). Med Lett Drugs Ther 2009;51:66–67.
273.
Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev Vaccines 2009;8:1501–1511.
274.
Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002;77:331–339.
275.
Quicke KM, Suthar MS. The innate immune playbook for restricting West Nile virus infection. Viruses 2013;5:2643–2658.
276.
Kalil AC, Devetten MP, Singh S, et al. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 2005;40:764–766.
277.
Chan-Tack KM, Forrest G. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. Scand J Infect Dis 2005;37:944–946.
278.
Amanna IJ, Raué H-P, Slifka MK. Development of a new hydrogen peroxide–based vaccine platform. Nat Med 2012;18:974–979.
279.
Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother 1989;33:2009–2011.
280.
McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997;99:261–267.
281.
Haddow AD, Haddow AD. The use of oral ribavirin in the management of La Crosse viral infections. Med Hypotheses 2009;72:190–192.
282.
McJunkin JE, Nahata MC, De Los Reyes EC, et al. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J 2011;30:860–865.
283.
Paessler S, Weaver SC. Vaccines for Venezuelan equine encephalitis. Vaccine 2009;27(Suppl. 4):D80-D85.
284.
Pittman PR, Makuch RS, Mangiafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 1996;14:337–343.
285.
Martin SS, Bakken RR, Lind CM, et al. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 2010;28:3143–3151.
286.
Shrestha B, Gottlieb D, Diamond MS. Infection and Injury of neurons by West Nile encephalitis virus. J Virol 2003;77:13203–13213.
287.
Liu Y, King N, Kesson A, Blanden RV, Müllbacher A. West Nile virus infection modulates the expression of class I and class II MHC antigens on astrocytes in vitro. Ann N Y Acad Sci 1988;540:483–485.
288.
Chen CJ, Liao SL, Kuo MD, Wang YM. Astrocytic alteration induced by Japanese encephalitis virus infection. Neuroreport 2000;11:1933–1937.
289.
Desai A, Shankar SK, Ravi V, Chandramuki A, Gourie-Devi M. Japanese encephalitis virus antigen in the human brain and its topographic distribution. Acta Neuropathol 1995;89:368–373.
290.
Chang C-Y, Li J-R, Chen W-Y, et al. Disruption of in vitro endothelial barrier integrity by Japanese encephalitis virus-Infected astrocytes. Glia 2015 May 8 [Epub ahead of print].
291.
Reyes MG, Gardner JJ, Poland JD, Monath TP. St Louis encephalitis. Quantitative histologic and immunofluorescent studies. Arch Neurol 1981;38:329–334.
292.
Cho H, Proll SC, Szretter KJ, Katze MG, Gale M, Diamond MS. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive stranded RNA viruses. Nat Med 2013;19:458–464.
293.
Mázló M, Szántó J. Morphological demonstration of the virus of tick-borne encephalitis in the human brain. Acta Neuropathol 1978;43:251–253.
294.
Dropulić B, Masters CL. Entry of neurotropic arboviruses into the central nervous system: an in vitro study using mouse brain endothelium. J Infect Dis 1990;161:685–691.
295.
Yin J, Gardner CL, Burke CW, Ryman KD, Klimstra WB. Similarities and differences in antagonism of neuron alpha/beta interferon responses by Venezuelan equine encephalitis and Sindbis alphaviruses. J Virol 2009;83:10036–10047.
296.
Kehn-Hall K, Narayanan A, Lundberg L, et al. Modulation of GSK-3β activity in Venezuelan equine encephalitis virus infection. PLoS One 2012;7:e34761.
297.
Roy CJ, Reed DS, Wilhelmsen CL, Hartings J, Norris S, Steele KE. Pathogenesis of aerosolized Eastern Equine Encephalitis virus infection in guinea pigs. Virol J 2009;6:170.
298.
Pekosz A, Phillips J, Pleasure D, Merry D, Gonzalez-Scarano F. Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention. J Virol.1996;70:5329–5335.
299.
Reed C, Steele KE, Honko A, Shamblin J, Hensley LE, Smith DR. Ultrastructural study of Rift Valley fever virus in the mouse model. Virology 2012;431:58–70.
300.
Smith DR, Steele KE, Shamblin J, et al. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010;407:256–267.
301.
Moy RH, Gold B, Molleston JM, et al. Antiviral autophagy restrictsRift Valley fever virus infection and is conserved from flies to mammals. Immunity 2014;40:51–65.
302.
Frolova MP, Isachkova LM, Shestopalova NM, Pogodina VV. Experimental encephalitis in monkeys caused by the Powassan virus. Neurosci Behav Physiol 1985;15:62–69.
303.
Gholam BI, Puksa S, Provias JP. Powassan encephalitis: a case report with neuropathology and literature review. CMAJ 1999;161:1419–1422.
Metadaten
Titel
Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis
verfasst von
Hamid Salimi
Matthew D. Cain
Robyn S. Klein
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 3/2016
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-016-0443-5

Weitere Artikel der Ausgabe 3/2016

Neurotherapeutics 3/2016 Zur Ausgabe

Commentary

Vagus Nerve Stimulation: Rapid versus Slow Cycling in a Laboratory Model

Review

Exosomes in Viral Disease

Editorial

Editorial

Current Perspectives

Flow Diversion for Intracranial Aneurysm Management: A New Standard of Care

Original Article

hVMAT2: A Target of Individualized Medication for Parkinson’s Disease

Review

Gene Editing for Treatment of Neurological Infections

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise